Epigenetic roles of KDM3B and KDM3C in tumorigenesis and their therapeutic implications

Advances in functional studies on epigenetic regulators have disclosed the vital roles played by diverse histone lysine demethylases (KDMs), ranging from normal development to tumorigenesis. Most of the KDMs are Jumonji C domain-containing (JMJD) proteins. Many of these KDMs remove methyl groups fro...

Full description

Saved in:
Bibliographic Details
Published in:Cell death & disease 2024-06, Vol.15 (6), p.451-10, Article 451
Main Authors: Yoo, Jung, Kim, Go Woon, Jeon, Yu Hyun, Lee, Sang Wu, Kwon, So Hee
Format: Article
Language:English
Subjects:
13/1
13/109
13/2
13/89
631/45/147
631/67/68/2486
692/53/2421
82/29
82/51
82/80
96/95
Animals
Antibodies
Biochemistry
Biomedical and Life Sciences
Cancer
Carcinogenesis - genetics
Carcinogenesis - metabolism
Carcinogenesis - pathology
Cell Biology
Cell Culture
Epigenesis, Genetic
Epigenetics
Heart diseases
Histone H3
Histones
Humans
Immunology
Infertility
Jumonji Domain-Containing Histone Demethylases - genetics
Jumonji Domain-Containing Histone Demethylases - metabolism
Life Sciences
Lysine
Metabolic syndrome
Neoplasms - genetics
Neoplasms - metabolism
Neoplasms - pathology
Proteins
Review
Review Article
Tumorigenesis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Advances in functional studies on epigenetic regulators have disclosed the vital roles played by diverse histone lysine demethylases (KDMs), ranging from normal development to tumorigenesis. Most of the KDMs are Jumonji C domain-containing (JMJD) proteins. Many of these KDMs remove methyl groups from histone tails to regulate gene transcription. There are more than 30 known KDM proteins, which fall into different subfamilies. Of the many KDM subfamilies, KDM3 (JMJD1) proteins specifically remove dimethyl and monomethyl marks from lysine 9 on histone H3 and other non-histone proteins. Dysregulation of KDM3 proteins leads to infertility, obesity, metabolic syndromes, heart diseases, and cancers. Among the KDM3 proteins, KDM3A has been largely studied in cancers. However, despite a number of studies pointing out their importance in tumorigenesis, KDM3B and KDM3C are relatively overlooked. KDM3B and KDM3C show context-dependent functions, showing pro- or anti-tumorigenic abilities in different cancers. Thus, this review provides a thorough understanding of the involvement of KDM3B and KDMC in oncology that should be helpful in determining the role of KDM3 proteins in preclinical studies for development of novel pharmacological methods to overcome cancer.
ISSN:2041-4889
2041-4889
DOI:10.1038/s41419-024-06850-z